BR112016022743A2 - Método para tratar e/ou evitar pelo menos uma cicatriz de acne, uso de uma combinação fixa de adapaleno e peróxido de benzoíla e composição - Google Patents

Método para tratar e/ou evitar pelo menos uma cicatriz de acne, uso de uma combinação fixa de adapaleno e peróxido de benzoíla e composição

Info

Publication number
BR112016022743A2
BR112016022743A2 BR112016022743A BR112016022743A BR112016022743A2 BR 112016022743 A2 BR112016022743 A2 BR 112016022743A2 BR 112016022743 A BR112016022743 A BR 112016022743A BR 112016022743 A BR112016022743 A BR 112016022743A BR 112016022743 A2 BR112016022743 A2 BR 112016022743A2
Authority
BR
Brazil
Prior art keywords
adapalene
benzoyl peroxide
fixed combination
composition
treat
Prior art date
Application number
BR112016022743A
Other languages
English (en)
Inventor
BOURDES Valérie
Martel Philippe
Rivier Michel
Reynier Philippe
Petit Laurent
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52780548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016022743(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of BR112016022743A2 publication Critical patent/BR112016022743A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

MÉTODO PARA TRATAR E/OU EVITAR PELO MENOS UMA CICATRIZ DE ACNE, USO DE UMA COMBINAÇÃO FIXA DE ADAPALENO E PERÓXIDO DE BENZOÍLA E COMPOSIÇÃO. A presente invenção diz respeito a um método para tratar e/ou prevenir as cicatrizes da acne no qual uma quantidade eficaz de uma composição que contém uma combinação fixa de adapaleno ou um de seus sais e peróxido de benzoíla é administrada em um paciente que necessita dela. A presente invenção diz respeito ainda a composição que contém uma combinação fixa de adapaleno ou um de seus sais e peróxido de benzoíla para seu uso para tratar e/ou evitar as cicatrizes da acne.
BR112016022743A 2014-04-01 2015-03-30 Método para tratar e/ou evitar pelo menos uma cicatriz de acne, uso de uma combinação fixa de adapaleno e peróxido de benzoíla e composição BR112016022743A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973350P 2014-04-01 2014-04-01
PCT/EP2015/056906 WO2015150332A1 (en) 2014-04-01 2015-03-30 Combination of adapalene and benzoyl peroxide for treating acne scars

Publications (1)

Publication Number Publication Date
BR112016022743A2 true BR112016022743A2 (pt) 2017-08-15

Family

ID=52780548

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016022743A BR112016022743A2 (pt) 2014-04-01 2015-03-30 Método para tratar e/ou evitar pelo menos uma cicatriz de acne, uso de uma combinação fixa de adapaleno e peróxido de benzoíla e composição

Country Status (11)

Country Link
US (1) US20170020833A1 (pt)
EP (1) EP3125880B1 (pt)
KR (2) KR20160130862A (pt)
AU (1) AU2015239688B2 (pt)
BR (1) BR112016022743A2 (pt)
CA (1) CA2944073A1 (pt)
CL (1) CL2016002489A1 (pt)
MX (1) MX2016012623A (pt)
RU (1) RU2016142678A (pt)
SG (2) SG10202100745QA (pt)
WO (1) WO2015150332A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022003367A2 (pt) * 2019-08-23 2022-05-17 Allergan Pharmaceuticals Int Ltd Tropoelastina para uso em tratamento de cicatrizes de acne
WO2023068233A1 (ja) * 2021-10-18 2023-04-27 マルホ株式会社 活性阻害及び／又は産生抑制剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833841B1 (fr) 2001-12-21 2005-07-22 Galderma Res & Dev Gel comprenant au moins un retinoide et du peroxyde de benzoyle
FR2901139B1 (fr) * 2006-05-17 2009-03-20 Galderma Res & Dev S N C Snc Compositions comprenant au moins un derive de l'acide naphtoique et du peroxyde de benzoyle, leurs procedes de preparation, et leurs utilisations
US8080537B2 (en) * 2006-07-13 2011-12-20 Galderma Research & Development Combinations of adapalene and benzoyl peroxide for treating acne lesions
FR2903603B1 (fr) * 2006-07-13 2009-03-20 Galderma Res & Dev S N C Snc Combinaison d'adapalene et de peroxyde de benzole dans le traitement de l'acne
EP2114392B1 (en) * 2007-01-30 2015-06-10 Galderma Research & Development Use of adapalene and benzoyl peroxide for the long term treatment of acne vulgaris
MX2012008871A (es) * 2010-02-09 2012-08-31 Galderma Res & Dev Composicion dermatologica que comprende combinacion de adapaleno y peroxido de benzoilo para el tratamiento del acne en poblacion no caucasica con reduccion de hiperpigmentacion post-inflamatoria.
CA2796412A1 (en) * 2010-04-29 2011-11-03 Galderma Research & Development Method for treating scars with adapalene 0.3%
EP3082785A1 (en) * 2013-12-19 2016-10-26 Galderma Research & Development Therapy regimen for treating severe acne related diseases

Also Published As

Publication number Publication date
CL2016002489A1 (es) 2017-02-03
EP3125880A1 (en) 2017-02-08
WO2015150332A1 (en) 2015-10-08
MX2016012623A (es) 2016-12-14
KR20160130862A (ko) 2016-11-14
CA2944073A1 (en) 2015-10-08
RU2016142678A (ru) 2018-05-07
AU2015239688A1 (en) 2016-10-13
US20170020833A1 (en) 2017-01-26
SG11201608222WA (en) 2016-10-28
EP3125880B1 (en) 2019-11-20
KR20220148939A (ko) 2022-11-07
AU2015239688B2 (en) 2020-06-25
SG10202100745QA (en) 2021-02-25

Similar Documents

Publication Publication Date Title
CO2020006009A2 (es) Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112016027588B8 (pt) Sistema de aplicação em camadas para uma composição para tratamento de pele e método para aplicação de múltiplas doses de uma ou mais composições em uma área de tratamento de pele
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
MX2017004580A (es) Combinaciones de auristatina sinergica.
CL2015002543A1 (es) Derivado de dihidropiridazin-3,5-diona.
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
CL2015002171A1 (es) Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
BR112017015576A2 (pt) método para o tratamento de câncer, artigo, método para monitorizar, método para a otimização da eficácia terapêutica, método para a identificação de um biomarcador, utilização, combinação terapêutica, combinação para a utilização e produto
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
BR112017000398A2 (pt) composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]